COMP <GO>
ORGO vs MRK // ENTERPRISE SCALE & MARKET CAP
Organogenesis Holdings Inc. (Class A) (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ORGO 1
— MRK 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MRK
LAST: $0.76 (-1.64%) • MKT CAP: $98.8M
market-cap
$98.8M
LAST: $148.36 (-0.78%) • MKT CAP: $368.89B
market-cap
$368.89B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORGO VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ORGO | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.10% | 20.70% | -3.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -23.21% | 3.42% | -26.63 | MRK | /fcf-yield <GO> |
| Operating Margin | 7.90% | 34.30% | -26.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 6.60% | 28.10% | -21.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 17.00% | 1.30% | +15.70 | ORGO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.09 | 5.19 | -3.10 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 20.2 | 56.3 | -36.10 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $98.8M | $368.89B | -$368.79B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ORGO REV | MRK REV | ORGO GROSS % | MRK GROSS % | ORGO FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $564.2M | $65.01B | — | 74.8% | -$24.5M | $12.36B |
| FY 2024 | $482.0M | $64.17B | 76.0% | 76.3% | $4.2M | $18.10B |
| FY 2023 | $433.1M | $60.12B | — | — | $30.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORGO // BETA —
MRK // BETA 0.92